Style | Citing Format |
---|---|
MLA | Moradi A, et al.. "Effect of Zataria Multiflora Supplementation on Pro- or Anti-Inflammatory Markers: A Systematic Review and Meta-Analysis of Randomized Placebo-Controlled Trials." Inflammopharmacology, vol. 33, no. 3, 2025, pp. 1255-1270. |
APA | Moradi A, Aslani F, Boskabady MH, Pahlavan Y, Aslani MR (2025). Effect of Zataria Multiflora Supplementation on Pro- or Anti-Inflammatory Markers: A Systematic Review and Meta-Analysis of Randomized Placebo-Controlled Trials. Inflammopharmacology, 33(3), 1255-1270. |
Chicago | Moradi A, Aslani F, Boskabady MH, Pahlavan Y, Aslani MR. "Effect of Zataria Multiflora Supplementation on Pro- or Anti-Inflammatory Markers: A Systematic Review and Meta-Analysis of Randomized Placebo-Controlled Trials." Inflammopharmacology 33, no. 3 (2025): 1255-1270. |
Harvard | Moradi A et al. (2025) 'Effect of Zataria Multiflora Supplementation on Pro- or Anti-Inflammatory Markers: A Systematic Review and Meta-Analysis of Randomized Placebo-Controlled Trials', Inflammopharmacology, 33(3), pp. 1255-1270. |
Vancouver | Moradi A, Aslani F, Boskabady MH, Pahlavan Y, Aslani MR. Effect of Zataria Multiflora Supplementation on Pro- or Anti-Inflammatory Markers: A Systematic Review and Meta-Analysis of Randomized Placebo-Controlled Trials. Inflammopharmacology. 2025;33(3):1255-1270. |
BibTex | @article{ author = {Moradi A and Aslani F and Boskabady MH and Pahlavan Y and Aslani MR}, title = {Effect of Zataria Multiflora Supplementation on Pro- or Anti-Inflammatory Markers: A Systematic Review and Meta-Analysis of Randomized Placebo-Controlled Trials}, journal = {Inflammopharmacology}, volume = {33}, number = {3}, pages = {1255-1270}, year = {2025} } |
RIS | TY - JOUR AU - Moradi A AU - Aslani F AU - Boskabady MH AU - Pahlavan Y AU - Aslani MR TI - Effect of Zataria Multiflora Supplementation on Pro- or Anti-Inflammatory Markers: A Systematic Review and Meta-Analysis of Randomized Placebo-Controlled Trials JO - Inflammopharmacology VL - 33 IS - 3 SP - 1255 EP - 1270 PY - 2025 ER - |